10-Q 1 form10q.htm U.S. PHYSICAL THERAPY, INC. 10-Q 9-30-2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

 
FORM 10-Q
 

 
(MARK ONE)
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE QUARTERLY PERIOD ENDED September 30, 2014
 
OR
 
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE TRANSITION PERIOD FROM             TO            
 
COMMISSION FILE NUMBER 1-11151
 

 
U.S. PHYSICAL THERAPY, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
 

 
NEVADA
 
76-0364866
(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)
 
(I.R.S. EMPLOYER IDENTIFICATION NO.)

1300 WEST SAM HOUSTON PARKWAY SOUTH,
 
 
SUITE 300, HOUSTON, TEXAS
 
77042
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
 
(ZIP CODE)
 
REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE: (713) 297-7000
 

 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    x  Yes     o  No
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    x  Yes     o  No
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer
o
Accelerated filer
x
       
Non-accelerated filer
o  (Do not check if a smaller reporting company)
Smaller reporting company
o
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    o  Yes    x  No
 
As of November 7, 2014, the number of shares outstanding (issued less treasury stock) of the registrant’s common stock, par value $.01 per share, was: 12,268,895.
 


PART I—FINANCIAL INFORMATION
 
Item 1.
3
 
 
3
 
 
4
 
 
5
 
 
6
 
 
7
 
Item 2.
20
 
Item 3.
27
 
Item 4.
27
 
PART II—OTHER INFORMATION
 
Item 6.
28
 
 
29
 
 
Certifications
 
ITEM 1. FINANCIAL STATEMENTS.
 
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
 
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE DATA)
 
   
September 30, 2014
   
December 31, 2013
 
ASSETS
  (unaudited)      
Current assets:
       
Cash and cash equivalents
 
15,824
   
12,898
 
Patient accounts receivable, less allowance for doubtful accounts of $1,811 and $1,430, respectively
   
33,809
     
30,820
 
Accounts receivable - other, less allowance for doubtful accounts of $198 and $198, respectively
   
1,906
     
1,844
 
Other current assets
   
5,076
     
4,098
 
Total current assets
   
56,615
     
49,660
 
Fixed assets:
               
Furniture and equipment
   
42,104
     
38,965
 
Leasehold improvements
   
22,639
     
21,891
 
     
64,743
     
60,856
 
Less accumulated depreciation and amortization
   
48,685
     
45,896
 
     
16,058
     
14,960
 
Goodwill
   
150,471
     
143,955
 
Other intangible assets, net
   
22,615
     
14,479
 
Other assets
   
1,978
     
1,081
 
   
247,737
   
224,135
 
                 
LIABILITIES AND SHAREHOLDERS' EQUITY
               
Current liabilities:
               
Accounts payable - trade
 
1,901
   
1,722
 
Accrued expenses
   
19,081
     
20,625
 
Current portion of notes payable
   
850
     
825
 
Total current liabilities
   
21,832
     
23,172
 
Notes payable
   
450
     
650
 
Revolving line of credit
   
46,500
     
40,000
 
Deferred rent
   
1,014
     
996
 
Other long-term liabilities
   
7,378
     
4,196
 
Total liabilities
   
77,174
     
69,014
 
Commitments and contingencies
               
Redeemable non-controlling interests
   
7,524
     
4,104
 
Shareholders' equity:
               
U. S. Physical Therapy, Inc. shareholders' equity:
               
Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding
   
-
     
-
 
Common stock, $.01 par value, 20,000,000 shares authorized, 14,480,632 and 14,315,882 shares issued, respectively
   
145
     
143
 
Additional paid-in capital
   
42,457
     
40,569
 
Retained earnings
   
130,683
     
119,206
 
Treasury stock at cost, 2,214,737 shares
   
(31,628
)
   
(31,628
)
Total U. S. Physical Therapy, Inc. shareholders' equity
   
141,657
     
128,290
 
Non-controlling interests
   
21,382
     
22,727
 
Total equity
   
163,039
     
151,017
 
   
247,737
   
224,135
 

See notes to consolidated financial statements.
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
 
CONSOLIDATED STATEMENTS OF NET INCOME
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(unaudited)

   
Three Months Ended
   
Nine Months Ended
 
   
September 30, 2014
   
September 30, 2013
   
September 30, 2014
   
September 30, 2013
 
Net patient revenues
 
76,184
   
$
64,368
   
$
221,051
   
$
191,027
 
Other revenues
   
1,532
     
1,460
     
4,633
     
4,426
 
Net revenues
   
77,716
     
65,828
     
225,684
     
195,453
 
Clinic operating costs:
                               
Salaries and related costs
   
41,802
     
35,733
     
119,853
     
105,318
 
Rent, clinic supplies, contract labor and other
   
16,117
     
12,877
     
45,538
     
38,161
 
Provision for doubtful accounts
   
1,090
     
1,095
     
3,094
     
3,390
 
Closure costs
   
(39
)
   
(5
)
   
(28
)
   
21
 
Total clinic operating costs
   
58,970
     
49,700
     
168,457
     
146,890
 
Gross margin
   
18,746
     
16,128
     
57,227
     
48,563
 
Corporate office costs
   
7,468
     
6,224
     
22,214
     
19,165
 
Operating income from continuing operations
   
11,278
     
9,904
     
35,013
     
29,398
 
Interest and other income, net
   
2
     
2
     
3
     
5
 
Interest expense
   
(237
)
   
(133
)
   
(822
)
   
(398
)
Income before taxes from continuing operations
   
11,043
     
9,773
     
34,194
     
29,005
 
Provision for income taxes
   
3,625
     
3,017
     
11,033
     
8,798
 
Net income from continuing operations including non-controlling interests
   
7,418
     
6,756
     
23,161
     
20,207
 
Discontinued operations, net of tax
   
-
     
(4,497
)
   
-
     
(4,965
)
Net income including non-controlling interests
   
7,418
     
2,259
     
23,161
     
15,242
 
Less: net income attributable to non-controlling interests
   
(2,202
)
   
(2,032
)
   
(7,285
)
   
(6,380
)
Net income attributable to common shareholders
 
5,216
   
227
   
15,876
   
8,862
 
Diluted earnings per share attributable to common shareholders:
                               
From continuing operations
 
0.43
   
0.38
   
1.30
   
1.13
 
Basic earnings per share attributable to common shareholders:
                               
From continuing operations
   
0.43
     
0.38
     
1.30
     
1.13
 
Revaluation of redeemable non-controlling interests, net of tax
   
-
     
-
     
(0.09
)
   
-
 
From discontinued operations
   
-
     
(0.36
)
   
-
     
(0.39
)
Basic
 
$
0.43
   
0.02
   
1.21
   
0.74
 
Diluted earnings per share attributable to common shareholders:
                               
From continuing operations
   
0.43
     
0.38
     
1.30
     
1.12
 
Revaluation of redeemable non-controlling interests, net of tax
   
-
     
-
     
(0.09
)
   
-
 
From discontinued operations
   
-
     
(0.36
)
   
-
     
(0.39
)
Diluted
 
0.43
   
0.02
   
1.21
   
0.73
 
Shares used in computation:
                               
Basic
   
12,244
     
12,106
     
12,201
     
12,050
 
Diluted
   
12,247
     
12,120
     
12,208
     
12,069
 
                                 
Dividends declared per common share
 
0.12
   
0.10
   
0.36
   
0.30
 
Earnings attributable to common shareholders:
                               
From continuing operations
   
5,216
     
4,659
     
15,876
     
13,589
 
From discontinued operations
   
-
     
(4,432
)
   
-
     
(4,727
)
   
5,216
   
227
   
15,876
   
8,862
 

See notes to consolidated financial statements.

U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
 
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(unaudited)
 
   
Nine Months Ended
 
   
September 30, 2014
   
September 30, 2013
 
OPERATING ACTIVITIES
       
Net income including non-controlling interests
 
23,161
   
15,242
 
Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities:
   
 
     
 
 
Depreciation and amortization
   
4,682
     
4,181
 
Provision for doubtful accounts
   
3,094
     
3,377
 
Equity-based awards compensation expense
   
2,456
     
2,092
 
Loss on sale of business and sale or abandonment of assets, net
   
20
     
7,233
 
Excess tax benefit from exercise of stock options
   
(526
)    
(277
)
Deferred income tax
   
3,888
     
(543
)
Changes in operating assets and liabilities:
               
Increase in patient accounts receivable
   
(4,952
)
   
(3,318
)
Increase in accounts receivable - other
   
(62
)
   
(41
)
(Increase) decrease in other assets
   
(1,803
)    
1,148
 
Decrease in accounts payable and accrued expenses
   
(1,739
)
   
(899
)
Increase in other Long term liabilities
   
607
 
   
664
 
Net cash provided by operating activities
   
28,826
     
28,859
 
INVESTING ACTIVITIES
   
-
         
Purchase of fixed assets
   
(3,912
)
   
(3,458
)
Purchase of businesses, net of cash acquired
   
(12,240
)
   
(10,128
)
Acquisitions of non-controlling interests
   
(4,998
)
   
(1,668
)
Proceeds on sale of business and fixed assets, net
   
43
     
448
 
Net cash used in investing activities
   
(21,107
)
   
(14,806
)
FINANCING ACTIVITIES
               
Distributions to non-controlling interests
   
(7,067
)
   
(6,588
)
Cash dividends to shareholders
   
(4,399
)
   
(3,628
)
Proceeds from revolving line of credit
   
112,300
     
88,450
 
Payments on revolving line of credit
   
(105,800
)
   
(91,700
)
Payment of notes payable
   
(575
)
   
(459
)
Excess tax benefit from stock options exercised
   
526
     
277
 
Proceeds from exercise of stock options
   
45
         
Other
   
177
     
47
 
Net cash used in financing activities
   
(4,793
)
   
(13,601
)
Net increase in cash
   
2,926
     
452
 
Cash - beginning of period
   
12,898
     
11,671
 
Cash - end of period
 
15,824
   
12,123
 
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
               
Cash paid during the period for:
               
Income taxes
 
7,920
   
4,402
 
Interest
 
857
   
352
 
Non-cash investing and financing transactions during the period:
               
Purchase of business - seller financing portion
 
400
   
800
 
Revaluation of redeemable non-controlling interests
 
1,841
   
-
 

See notes to consolidated financial statements.
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
 
CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY
(IN THOUSANDS)
(unaudited)

   
Common Stock Shares
   
Common Stock Amount
   
Additional Paid-In Capital
   
Retained Earnings
   
Treasury Stock Shares
   
Treasury Stock Amount
   
Total Shareholders' Equity
   
Non- controlling Interests
   
Total
 
Balance December 31, 2013
 
14,316
   
143
   
40,569
   
119,206
   
(2,215
)
 
(31,628
)
 
128,290
   
22,727
   
151,017
 
Issuance of restricted stock, net of cancellations
   
147
     
1
     
-
     
-
     
-
     
-
     
1
     
-
     
1
 
Proceeds from exercise of stock options
   
18
     
1
     
43
     
-
     
-
     
-
     
44
     
-
     
44
 
Compensation expense - restricted stock
   
-
     
-
     
2,456
     
-
     
-
     
-
     
2,456
     
-
     
2,456
 
Excess tax benefit of equity grants
   
-
     
-
     
526
     
-
     
-
     
-
     
526
     
-
     
526
 
Purchase of business
   
-
     
-
     
-
     
-
     
-
     
-
     
-
     
4,725
     
4,725
 
Revaluation of redeemable non-controlling interests, net of tax
   
-
     
-
     
(1,086
)
   
-
     
-
     
-
     
(1,086
)
   
-
     
(1,086
)
Reclass to redeemable non- controlling interests
                                                           
(6,438
)
   
(6,438
)
Acquisition of non-controlling interests
   
-
     
-
     
(51
)
   
-
     
-
     
-
     
(51
)
   
(27
)
   
(78
)
Dividends paid to shareholders
   
-
     
-
     
-
     
(4,399
)
   
-
     
-
     
(4,399
)
   
-
     
(4,399
)
Contributions of non-controlling interest partner
                                                           
177
     
177
 
Distributions to non-controlling interest partners
   
-
     
-
     
-
     
-
     
-
     
-
     
-
     
(7,067
)
   
(7,067
)
Net income
   
-
     
-
     
-
     
15,876
     
-
     
-
     
15,876
     
7,285
     
23,161
 
Balance September 30, 2014
 
14,481
   
145
   
42,457
   
130,683
   
(2,215
)
 
(31,628
)
 
141,657
   
21,382
   
163,039
 


See notes to consolidated financial statements.
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2014
(unaudited)

1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
 
The consolidated financial statements include the accounts of U.S. Physical Therapy, Inc. and its subsidiaries (the “Company”). All significant intercompany transactions and balances have been eliminated. The Company primarily operates through subsidiary clinic partnerships, in which the Company generally owns a 1% general partnership interest and a 64% limited partnership interest. The managing therapist of each clinic owns, directly or indirectly, the remaining limited partnership interest in the majority of the clinics (hereinafter referred to as “Clinic Partnerships”). To a lesser extent, the Company operates some clinics, through wholly-owned subsidiaries, under profit sharing arrangements with therapists (hereinafter referred to as “Wholly-Owned Facilities”).
 
The Company continues to seek to attract physical and occupational therapists who have established relationships with patients and physicians by offering therapists a competitive salary and a share of the profits of the clinic operated by that therapist. The Company has developed satellite clinic facilities of existing clinics, with the result that many Clinic Partnerships and Wholly-Owned Facilities operate more than one clinic location. In addition, the Company has acquired a controlling interest in a number of clinics through acquisitions.
 
During the first nine months of 2014 and the year ended 2013, the Company acquired the following clinic groups:
 
      
% Interest
   
Number of
 
Acquisition
Date
 
Acquired
   
Clinics
 
           
  2014
April 2014 Acquisition
April 30
   
70%
   
13
 
August 2014 Acquisition
August 1
   
100%
   
3
 
                   
  2013
February 2013 Acquisition
February 28
   
72%
   
9
 
April 2013 Acquisition
April 30
   
50%
   
5
 
May 2013 Acquisition
May 24
   
80%
   
5
 
December 9, 2013 Acquisition
December 9
   
60%
   
12
 
December 13, 2013 Acquisition
December 13
   
90%
   
11
 

In addition to the clinic groups noted in the table above, during the nine months ended September 30, 2014, the Company acquired three individual clinics in separate transactions.  Two of the acquired clinics will operate as a satellite of two separate partnerships of the Company and the other will be consolidated into an existing clinic.  In 2013, the Company, through three of its subsidiaries, acquired three individual physical therapy clinics in separate transactions.
 
As of September 30, 2014, the Company operated 489 clinics in 42 states.
 
The results of operations of the acquired clinics have been included in the Company’s consolidated financial statements since the date of their respective acquisition.
 
The Company intends to continue to focus on pursuing additional acquisition opportunities, developing new clinics and opening satellite clinics.
 
The accompanying unaudited consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions for Form 10-Q. However, the statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. Management believes this report contains all necessary adjustments (consisting only of normal recurring adjustments) to present fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. For further information regarding the Company’s accounting policies, please read the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
 
The Company believes, and the Chief Executive Officer, Chief Financial Officer and Corporate Controller have certified, that the financial statements included in this report present fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented.
 
Operating results for the three and nine months ended September 30, 2014 are not necessarily indicative of the results the Company expects for the entire year. Please also review the Risk Factors section included in our Annual Report on Form 10-K for the year ended December 31, 2013.
 
Clinic Partnerships
 
For Clinic Partnerships, the earnings and liabilities attributable to the non-controlling interests, typically owned by the managing therapist, directly or indirectly, are recorded within the balance sheets and income statements as non-controlling interests.
 
Wholly-Owned Facilities
 
For Wholly-Owned Facilities with profit sharing arrangements, an appropriate accrual is recorded for the amount of profit sharing due to the profit sharing therapists. The amount is expensed as compensation and included in clinic operating costs – salaries and related costs. The respective liability is included in current liabilities – accrued expenses on the balance sheet.
 
Significant Accounting Policies
 
Long-Lived Assets
 
Fixed assets are stated at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the assets. Estimated useful lives for furniture and equipment range from three to eight years and for software purchased from three to seven years. Leasehold improvements are amortized over the shorter of the lease term or estimated useful lives of the assets, which is generally three to five years.
 
Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of
 
The Company reviews property and equipment and intangible assets with finite lives for impairment upon the occurrence of certain events or circumstances which indicate that the amounts may be impaired. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
 
Goodwill
 
Goodwill represents the excess of the amount paid and fair value of the non-controlling interests over the fair value of the acquired business assets, which include certain intangible assets. Historically, goodwill has been derived from acquisitions and, prior to 2009, from the purchase of some or all of a particular local management’s equity interest in an existing clinic. Effective January 1, 2009, if the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall, as applicable, is recognized as an adjustment to additional paid-in capital.
 
The fair value of goodwill and other intangible assets with indefinite lives are tested for impairment annually and upon the occurrence of certain events, and are written down to fair value if considered impaired. The Company evaluates goodwill for impairment on at least an annual basis (in its third quarter) by comparing the fair value of its reporting units to the carrying value of each reporting unit including related goodwill. The Company operates a one segment business which is made up of various clinics within partnerships. The partnerships are components of regions and are aggregated to that operating segment level for the purpose of determining the Company’s reporting units when performing its annual goodwill impairment test.  In 2014, there are six regions.
 
An impairment loss generally would be recognized when the carrying amount of the net assets of a reporting unit, inclusive of goodwill and other intangible assets, exceeds the estimated fair value of the reporting unit. The estimated fair value of a reporting unit is determined using two methods: (i) earnings prior to taxes, depreciation and amortization for the reporting unit multiplied by a put price/earnings ratio used in the industry and (ii) a discounted cash flow analysis. A weight is assigned to each method used and the weighted sum of the two methods is considered the estimated fair value. For 2014, the factors (i.e., price/earnings ratio, discount rate and residual capitalization rate) were updated to reflect current market conditions. The evaluations in the third quarter of 2014 and 2013 did not yield any impairment charge. During the nine months ended September 30, 2014, the Company did not identify any triggering events occurring after the testing date that would impact the impairment testing results obtained.
 
Non-controlling interests
 
The Company recognizes non-controlling interests as equity in the consolidated financial statements separate from the parent entity’s equity. The amount of net income attributable to non-controlling interests is included in consolidated net income on the face of the income statement. Changes in a parent entity’s ownership interest in a subsidiary that do not result in deconsolidation are treated as equity transactions if the parent entity retains its controlling financial interest. The Company recognizes a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss is measured using the fair value of the non-controlling interest on the deconsolidation date.
 
When the purchase price of a non-controlling interest by the Company exceeds or is less than the book value at the time of purchase, any excess or shortfall, as applicable, is recognized as an adjustment to additional paid-in capital. Additionally, operating losses are allocated to non-controlling interests even when such allocation creates a deficit balance for the non-controlling interest partner.
 
The non-controlling interests that are reflected as redeemable non-controlling interests in the consolidated financial statements consist of those owners who have certain redemption rights that are currently exercisable, and that, if exercised, require that the Company purchase the non-controlling interest of the particular limited partner.  The redeemable non-controlling interests are adjusted to the fair value, generally based on a mutliple times the trailing twelve months of earnings before interest, taxes, amortization and depreciation, in the reporting period in which the Company deems it probable that the limited partner will assert the redemption rights and will be adjusted each reporting period thereafter.  The adjustments are charged to additional paid-in capital and are not reflected in the statement of net income.  Although the adjustments are not reflected in the statement of net income, current accounting rules require that the Company reflects the charge in the earnings per share calculation.
 
Typically, for acquisitions, the Company agrees to purchase the individual’s non-controlling interest at a predetermined multiple of earnings before interest, taxes, depreciation and amortization.
 
Revenue Recognition
 
Revenues are recognized in the period in which services are rendered. Net patient revenues (patient revenues less estimated contractual adjustments) are reported at the estimated net realizable amounts from third-party payors, patients and others for services rendered. The Company has agreements with third-party payors that provide for payments to the Company at amounts different from its established rates. The allowance for estimated contractual adjustments is based on terms of payor contracts and historical collection and write-off experience.
 
The Company determines allowances for doubtful accounts based on the specific agings and payor classifications at each clinic. The provision for doubtful accounts is included in clinic operating costs in the statement of net income. Net accounts receivable, which are stated at the historical carrying amount net of contractual allowances, write-offs and allowance for doubtful accounts, includes only those amounts the Company estimates to be collectible.
 
Medicare Reimbursement
 
The Medicare program reimburses outpatient rehabilitation providers based on the Medicare Physician Fee Schedule (“MPFS”). The MPFS rates are automatically updated annually based on a formula, called the sustainable growth rate (“SGR”) formula. The use of the SGR formula would have resulted in calculated automatic reductions in rates in every year since 2002; however, for each year through June 30, 2014, Centers for Medicare & Medicaid Services (“CMS”) or Congress has taken action to prevent the implementation of SGR formula reductions. The Bipartisan Budget Act of 2013 froze the Medicare physician fee schedule rates at 2013 levels through June 30, 2014, averting a scheduled 20.1% cut in the MPFS as a result of the SGR formula that would have taken effect on January 1, 2014. The Protecting Access to Medicare Act of 2014 temporarily blocks this reduction through March 31, 2015 and replaces it with a 0.5% payment increase for services provided through December 31, 2014. In October 2014, CMS released the Medicare physician fee schedule rates for 2015, which includes a 1% payment increase for physical therapy services.  Automatic reductions in the Medicare physician fee schedule payment rates will commence on April 1, 2015, unless Congress again takes legislative action to prevent the SGR formula reductions from going into effect.
 
The Budget Control Act of 2011 increased the federal debt ceiling in connection with deficit reductions over the next ten years, and requires automatic reductions in federal spending by approximately $1.2 trillion. Payments to Medicare providers are subject to these automatic spending reductions, subject to a 2% cap.  On April 1, 2013, a 2% reduction to Medicare payments was implemented.
 
As a result of the Balanced Budget Act of 1997, the formula for determining the total amount paid by Medicare in any one year for outpatient physical therapy, occupational therapy, and/or speech-language pathology services provided to any Medicare beneficiary (i.e., the “Therapy Cap” or “Limit”) was established. Based on the statutory definitions which constrained how the Therapy Cap would be applied, there is one Limit for Physical Therapy and Speech Language Pathology Services combined, and one Limit for Occupational Therapy.  Since January 1, 2014, the annual Limit on outpatient therapy services is $1,920 for Physical and Speech Language Pathology Services combined and $1,920 for Occupational Therapy Services.  Starting January 1, 2015, the annual Limits will be increased to $1,940.   Historically, these Therapy Caps applied to outpatient therapy services provided in all settings, except for services provided in departments of hospitals. However, the Protecting Access to Medicare Act of 2014, and prior legislation, extended the annual limits on therapy expenses and the manual medical review thresholds to services furnished in hospital outpatient department settings through March 31, 2015. The application of annual limits will no longer apply to hospital outpatient department settings commencing as of March 31, 2015 unless Congress extends it.
 
In the Deficit Reduction Act of 2005, Congress implemented an exceptions process to the annual Limit for therapy expenses for therapy services above the annual Limit.  Therapy services above the annual Limit that are medically necessary satisfy an exception to the annual Limit and such claims are payable by the Medicare program. The Protecting Access to Medicare Act of 2014 extended the exceptions process for outpatient therapy caps through March 31, 2015.   Unless Congress extends the exceptions process further, the therapy caps will apply to all outpatient therapy services beginning April 1, 2015, except those services furnished and billed by outpatient hospital departments.  For any claim above the annual Limit, the claim must contain a modifier indicating that the services are medically necessary and justified by appropriate documentation in the medical record.
 
Furthermore, under the Middle Class Tax Relief and Job Creation Act of 2012 (“MCTRA”), since October 1, 2012, patients who met or exceeded $3,700 in therapy expenditures during a calendar year have been subject to a manual medical review to determine whether applicable payment criteria are satisfied. The $3,700 threshold is applied to Physical Therapy and Speech Language Pathology Services; a separate $3,700 threshold is applied to the Occupational Therapy. The Protecting Access to Medicare Act of 2014 extended through March 31, 2015 the requirement that Medicare perform manual medical review of therapy services beyond the $3,700 threshold.
 
CMS adopted a multiple procedure payment reduction (“MPPR”) for therapy services in the final update to the MPFS for calendar year 2011. During 2011, the MPPR applied to all outpatient therapy services paid under Medicare Part B — occupational therapy, physical therapy and speech-language pathology. Under the policy, the Medicare program pays 100% of the practice expense component of the Relative Value Unit (“RVU”) for the therapy procedure with the highest practice expense RVU, then reduces the payment for the practice expense component for the second and subsequent therapy procedures or units of service furnished during the same day for the same patient, regardless of whether those therapy services are furnished in separate sessions. In 2011 and 2012, the practice expense component for the second and subsequent therapy service furnished during the same day for the same patient was reduced by 20% in office and other non-institutional settings and by 25% in institutional settings. The American Taxpayer Relief Act of 2012 increased the payment reduction of the practice expense component to 50%, on subsequent therapy procedures in either setting, effective April 1, 2013. In addition, the Middle Class Tax Relief and Job Creation Act of 2012 (“MCTRA”) directed CMS to implement a claims-based data collection program to gather additional data on patient function during the course of therapy in order to better understand patient conditions and outcomes. All practice settings that provide outpatient therapy services are required to include this data on the claim form. Since July 1, 2013, therapists have been required to report new codes and modifiers on the claim form that reflect a patient’s functional limitations and goals at initial evaluation, periodically throughout care, and at discharge. Since July 1, 2013, CMS has rejected claims if the required data is not included in the claim.
 
The Physician Quality Reporting System, or "PQRS," is a CMS reporting program that uses a combination of incentive payments and payment reductions to promote reporting of quality information by "eligible professionals." Although physical therapists, occupational therapists and qualified speech-language therapists are generally able to participate in the PQRS program, therapy professionals for whose services we bill through our rehab agencies cannot participate because the Medicare claims processing systems currently cannot accommodate institutional providers such as rehab agencies. Eligible professionals, such as those of our therapy professionals for whose services we bill using their individual Medicare provider numbers, who do not satisfactorily report data on quality measures will be subject to a 2% reduction in their Medicare payment in 2016 and 2017.
 
Statutes, regulations, and payment rules governing the delivery of therapy services to Medicare beneficiaries are complex and subject to interpretation. The Company believes that it is in compliance in all material respects with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing that would have a material effect on the Company’s financial statements as of September 30, 2014. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare program.
 
Management Contract Revenues
 
Management contract revenues are derived from contractual arrangements whereby the Company manages a clinic for third party owners. The Company does not have any ownership interest in these clinics. Typically, revenues are determined based on the number of visits conducted at the clinic and recognized when services are performed. Costs, typically salaries for the Company’s employees, are recorded when incurred. Management contract revenues are included in “other revenues” in the accompanying Consolidated Statements of Net Income.
 
Contractual Allowances
 
Contractual allowances result from the differences between the rates charged for services performed and expected reimbursements for such services by both insurance companies and government sponsored healthcare programs. Medicare regulations and the various third party payors and managed care contracts are often complex and may include multiple reimbursement mechanisms payable for the services provided in Company clinics. The Company estimates contractual allowances based on its interpretation of the applicable regulations, payor contracts and historical calculations. Each month the Company estimates its contractual allowance for each clinic based on payor contracts and the historical collection experience of the clinic and applies an appropriate contractual allowance reserve percentage to the gross accounts receivable balances for each payor of the clinic. Based on the Company’s historical experience, calculating the contractual allowance reserve percentage at the payor level is sufficient to allow it to provide the necessary detail and accuracy with its collectibility estimates. However, the services authorized and provided and related reimbursement are subject to interpretation that could result in payments that differ from the Company’s estimates. Payor terms are periodically revised necessitating continual review and assessment of the estimates made by management. The Company’s billing systems may not capture the exact change in its contractual allowance reserve estimate from period to period in order to assess the accuracy of its revenues, and hence, its contractual allowance reserves. Management regularly compares its cash collections to corresponding net revenues measured both in the aggregate and on a clinic-by-clinic basis. In the aggregate, the difference between net revenues and corresponding cash collections has historically reflected a difference within approximately 1% of net revenues. Additionally, analysis of subsequent period’s contractual write-offs on a payor basis shows a less than 1% difference between the actual aggregate contractual reserve percentage as compared to the estimated contractual allowance reserve percentage associated with the same period end balance. As a result, the Company believes that a change in the contractual allowance reserve estimate would not likely be more than 1% at September 30, 2014.
 
Income Taxes
 
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and
operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
 
The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount to be recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Based on the Company's assessment, there are no uncertain tax positions at September 30, 2014 and December 31, 2013.
 
The Company recognizes accrued interest expense and penalties associated with unrecognized tax benefits as income tax expense. The Company did not have any accrued interest or penalties associated with any unrecognized tax benefits nor was any interest expense recognized during the three and nine months ended September 30, 2014 and 2013.
 
On September 13, 2013, the U.S. Treasury Department and the I.R.S. issued final regulations that address costs incurred in acquiring, producing, or improving tangible property (the “Tangible Property Regulations”).  The Tangible Property Regulations are generally effective for tax years beginning on or after January 1, 2014, and may be adopted in earlier years.  The Company adopted the tax treatment of expenditures to improve tangible property and the capitalization of inherently facilitative costs to acquire tangible property as of January 1, 2014.  Historically, the Company has treated the expenditures to improve tangible property and the capitalization of inherently facilitative costs to acquire tangible property similar for tax and book.  Management does not anticipate the impact of these changes to be material to the Company’s consolidated financial statements.
 
Fair Value of Financial Instruments
 
The carrying amounts reported in the balance sheet for cash and cash equivalents, accounts receivable, accounts payable and notes payable approximate their fair values due to the short-term maturity of these financial instruments. The carrying amount of the Company’s revolving line of credit approximates its fair value. The interest rate on the revolving line of credit, which is tied to the Eurodollar Rate, is set at various short-term intervals as detailed in the Credit Agreement (as defined in Note 9).
 
Segment Reporting
 
Operating segments are components of an enterprise for which separate financial information is available that is evaluated regularly by chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company identifies operating segments based on management responsibility and believes it meets the criteria for aggregating its operating segments into a single reporting segment.
 
Use of Estimates
 
In preparing the Company’s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, purchase accounting, goodwill impairment, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates.
 
Self-Insurance Program
 
The Company utilizes a self-insurance plan for its employee group health insurance coverage administered by a third party. Predetermined loss limits have been arranged with the insurance company to minimize the Company’s maximum liability and cash outlay. Accrued expenses include the estimated incurred but unreported costs to settle unpaid claims and estimated future claims. Management believes that the current accrued amounts are sufficient to pay claims arising from self-insurance claims incurred through September 30, 2014.
 
Restricted Stock
 
Restricted stock issued to employees and directors is subject to certain conditions, including continued employment or continued service on our Board of Directors (the “Board”), respectively. The transfer restrictions for shares granted to directors lapse in four equal quarterly installments and those to employees lapse in equal installments on the following four or five annual anniversaries of the date of grant. Compensation expense for grants of restricted stock is recognized based on the fair value per share on the date of grant amortized over the service period. The restricted stock issued is included in basic and diluted shares for the earnings per share computation.
 
Recently Issued Accounting Guidance
 
In April 2014, the Financial Accounting Standards Board issued changes to reporting discontinued operations and disclosures of disposals of components of an entity. These changes require a disposal of a component to meet a higher threshold in order to be reported as a discontinued operation in an entity’s financial statements. The threshold is defined as a strategic shift that has, or will have, a major effect on an entity’s operations and financial results such as a disposal of a major geographical area or a major line of business. Additionally, the following two criteria have been removed from consideration of whether a component meets the requirements for discontinued operations presentation: (i) the operations and cash flows of a disposal component have been or will be eliminated from the ongoing operations of an entity as a result of the disposal transaction, and (ii) an entity will not have any significant continuing involvement in the operations of the disposal component after the disposal transaction. Furthermore, equity method investments now may qualify for discontinued operations presentation. These changes also require expanded disclosures for all disposals of components of an entity, whether or not the threshold for reporting as a discontinued operation is met, related to profit or loss information and/or asset and liability information of the component. These changes become effective for the Company on January 1, 2015. Management has determined that the adoption of these changes will not have an immediate impact on the Consolidated Financial Statements.
2. EARNINGS PER SHARE
 
The computations of basic and diluted earnings per share for the Company are as follows (in thousands, except per share data):

   
Three Months Ended
   
Three Months Ended
   
Nine Months Ended
   
NIne Months Ended
 
   
September 30, 2014
   
September 30, 2013
   
September 30, 2014
   
September 30, 2013
 
Earnings attributable to common shareholders:
               
From continuing operations
 
5,216
   
$
4,659
   
15,876
   
13,589
 
From discontinued operations
   
-
     
(4,432
)
   
-
     
(4,727
)
     
5,216
     
227
     
15,876
     
8,862
 
Revaluation of redeemable non-controlling interests, net of tax
   
-
     
-
     
(1,086
)
   
-
 
   
5,216
   
227
   
14,790
   
8,862
 
                                 
Diluted earnings per share attributable to common shareholders:
                               
From continuing operations
 
0.43
   
0.38
   
1.30
   
1.13
 
                                 
Basic earnings per share attributable to common shareholders:
                               
From continuing operations
   
0.43
     
0.38
     
1.30
     
1.13
 
Charges to additional-paid-in-capital  - revaluation of redeemable non-controlling interests, net of tax
   
-
     
-
     
(0.09
)
   
-
 
From discontinued operations
   
-
     
(0.36
)
   
-
     
(0.39
)
Basic
 
0.43
   
0.02
   
1.21
   
0.74
 
Diluted earnings per share attributable to common shareholders:
                               
From continuing operations
   
0.43
     
0.38
     
1.30
     
1.12
 
Charges to additional-paid-in-capital - revaluation of redeemable non-controlling interests, net of tax
   
-
     
-
     
(0.09
)
   
-
 
From discontinued operations
   
-
     
(0.36
)
   
-
     
(0.39
)
Diluted
 
0.43
   
0.02
   
1.21
   
0.73
 
Shares used in computation:
                               
Basic earnings per share - weighted-average shares
   
12,244
     
12,106
     
12,201
     
12,050
 
Effect of dilutive securities - stock options
   
3
     
14
     
7
     
19
 
Denominator for diluted earnings per share - adjusted weighted-average shares
   
12,247
     
12,120
     
12,208
     
12,069
 

All options to purchase shares were included in the diluted earnings per share calculation for the three and nine months ended September 30, 2014 and 2013 as the average market prices of the common stock was above the exercise prices. The Company’s restricted stock issued is included in basic and diluted shares for the earnings per share computation from the date of grant.

The charges to additional paid-in capital – revaluation of redeemable non-controlling interests, net of tax represent the increase in the fair value of the redeemable non-controlling interest that were deemed probable that the owners would assert the redemption rights. See Note 1 – Basis of Presentation and Significant Accounting Policies – Significant Accounting Policies - Non-controlling interests.

3. ACQUISITIONS OF BUSINESSES

On April 30, 2014, the Company acquired a 70% interest in a 13-clinic physical therapy practice.  The purchase price for the 70% interest was $10,625,000 in cash and $400,000 in a seller note that is payable in two principal installments totaling $200,000 each, plus accrued interest, in April 2015 and 2016. On August 1, 2014, the Company acquired all of the interest in a 3-clinic physical therapy practice. The purchase price for the 100% interest was $1,050,000 in cash.   In addition, during the nine months ended September 30, 2014, the Company acquired three individual clinic practices for an aggregate of $565,000 in cash.
 
The purchase prices for the 2014 acquisitions have been preliminarily allocated as follows (in thousands):
 
Cash paid, net of cash acquired
 
12,240
 
Seller notes
   
400
 
Total consideration
   
12,640
 
Estimated fair value of net tangible assets acquired:
       
Total current assets
   
1,273
 
Total non-current assets
   
1,200
 
Total liabilities
   
(374
)
Net tangible assets acquired
   
2,099
 
Referral relationships
   
-
 
Non-competition agreements
   
-
 
Tradename
   
-
 
Goodwill
   
15,266
 
Fair value of non-controlling interest
   
(4,725
)
   
12,640
 

During 2013, the Company completed the following multi-clinic acquisitions of physical therapy practices:

      
%
Interest
   
Number
of
 
Acquisition
Date
 
Acquired
   
Clinics
 
           
February 2013 Acquisition
February 28
   
72%
   
9
 
April 2013 Acquisition
April 30
   
50%
   
5
 
May 2013 Acquisition
May 24
   
80%
   
5
 
December 9, 2013 Acquisition
December 9
   
60%
   
12
 
December 13, 2013 Acquisition
December 13
   
90%
   
11
 

In addition to the five multi-clinic acquisitions detailed above, in 2013, the Company acquired three individual clinics in separate transactions.
 
The purchase price for the 72% interest in the February 2013 Acquisition was $4.3 million in cash and $400,000 in a seller note, that is payable in two principal installments totaling $200,000 each, plus accrued interest, in February 2014 and 2015. The purchase price for the 50% interest in the April 2013 Acquisition was $2.4 million in cash and $200,000 in a seller note, that is payable in two principal installments totaling $100,000 each, plus accrued interest, in April of 2014 and 2015. The purchase price for the 80% interest in the May 2013 Acquisition was $3.6 million in cash and $200,000 in a seller note, that is payable in two principal installments totaling $100,000 each, plus accrued interest, in May of 2014 and 2015. The purchase price for the 60% interest in the December 9, 2013 Acquisition was $1.7 million in cash. The purchase price for the 90% interest in the December 13, 2013 Acquisition was $35.5 million in cash and $500,000 in a seller note, that is payable in two principal installments totaling $250,000 each, plus accrued interest, in December 2014 and 2015.
 
On February 1, 2013, through a subsidiary, the Company acquired a 100% interest in a clinic for $5,000. On June 1, 2013, the Company acquired a 100% interest in a clinic for $95,000. On September 16, 2013, the Company acquired a 100% interest in a clinic for $130,000.
 
The purchase prices for the 2013 acquisitions have been preliminarily allocated as follows (in thousands):
 
Cash paid, net of cash acquired
 
$
46,598
 
Seller notes
   
1,300
 
Total consideration
 
$
47,898
 
Estimated fair value of net tangible assets acquired:
       
Total current assets
 
$
3,712
 
Total non-current assets
   
1,971
 
Total liabilities
   
(1,082
)
Net tangible assets acquired
   
4,601
 
Referral relationships
   
6,140
 
Non-competition agreements
   
1,000
 
Tradename
   
3,200
 
Goodwill
   
43,498
 
Fair value of non-controlling interest
   
(10,541
)
   
$
47,898
 

The consideration for each transaction was agreed upon through arm’s length negotiations. Funding for the cash portion of the purchase price for the 2014 and 2013 acquisitions was derived from proceeds under the Credit Agreement.
 
The results of operations of these acquisitions have been included in the Company’s consolidated financial statements since acquired.
 
For the 2014 acquisitions and the two acquisitions which occurred in December, 2013, the purchase price plus the fair value of the non-controlling interest for those two acquisitions was allocated to the fair value of the assets acquired and liabilities assumed based on the preliminary estimates of the fair values at the acquisition date, with the amount exceeding the estimated fair values being recorded as goodwill. The Company is in the process of completing its formal valuation analysis to identify and determine the fair value of tangible and identifiable intangible assets acquired and the liabilities assumed. Thus, the final allocation of the purchase price may differ from the preliminary estimates used based on additional information obtained. Changes in the estimated valuation of the tangible and intangible assets acquired and the completion by the Company of the identification of any unrecorded pre-acquisition contingencies, where the liability is probable and the amount can be reasonably estimated, will likely result in adjustments to goodwill.
 
Except for the December 13, 2013 Acquisition, unaudited proforma consolidated financial information for acquisitions occurring in 2014 and 2013 have not been included as the results were not material to current operations.
 
Unaudited proforma net revenue and net income from continuing operations for the Company as if the December 13, 2013 Acquisition occurred as of January 1, 2013 is as follows (in thousands, except per share data):

   
Three Months Ended
   
Nine Months Ended
 
   
September 30, 2013
   
September 30, 2013
 
         
Net revenues
 
69,174
   
204,198
 
Net income attributable to common shareholders from continuing operations
 
5,273
   
15,023
 
                 
Earnings per share:
               
Basic - net income attributable to common shareholders from continuing operations
 
0.44
   
1.25
 
Diluted - net income attributable to common shareholders from continuing operations
 
0.44
   
1.24
 
                 
Shares used in computation:
               
Basic - net income attributable to common shareholders from continuing operations
   
12,106
     
12,050
 
Diluted - net income attributable to common shareholders from continuing operations
   
12,120
     
12,069
 
4. ACQUISITIONS AND REVALUATIONS OF NON-CONTROLLING INTERESTS
 
In four separate transactions during the nine months ended September 30, 2014, the Company purchased interests in two partnerships which were previously classified as redeemable non-controlling interest. The interests in the partnerships purchased ranged from 10.0% to 35.0%. The aggregate of the purchase prices paid was $4.9 million, which included $3.0 million of net book value. The remaining purchase price of $1.9 million, less future tax benefits of $0.8 million, was recognized as an adjustment to additional paid-in capital.
 
For the nine months ended September 30, 2014, the following table details the changes in the carrying amount of redeemable non-controlling interest:
 
   
Nine Months Ended
 
   
September 30, 2014
 
Beginning balance
 
4,104
 
Increase due to revaluation  and operating results of redeemable non-controlling interests
   
1,932
 
Reclass of non controlling interest
   
6,375
 
Purchases of redeemable non-controlling interests
   
(4,887
)
Ending balance
 
7,524
 

The non-controlling interests that are reflected as redeemable non-controlling interests in the consolidated financial statements consist of those owners who have certain redemption rights that are currently exercisable, and that, if exercised, require that the Company purchase the non-controlling interest of those owners.  The redeemable non-controlling interests are adjusted to the fair value in the reporting period in which the Company deems it probable that the limited partner will assert the redemption rights and it will be adjusted each reporting period thereafter.  The adjustments are charged to additional paid-in capital and are not reflected in the statement of net income.  Although the adjustments are not reflected in the statement of net income, current accounting rules require that the Company reflects the charge in the earnings per share calculation.

5. DISCONTINUED OPERATIONS
 
On September 30, 2013, the Company sold the remainder of its physician services business. Previously, the Company closed its two physician services facilities – one in August 2013 and the other in December 2012. As previously disclosed in the Company’s public filings, the physician services business incurred negative gross margins in 2012 and through the first nine months of 2013. The results of operations and the loss on the sale of the physician services business have been reclassified to discontinued operations for all periods presented.
 
The following table details the losses from discontinued operations reported for the physician services business:

   
Three Months Ended
   
Nine Months Ended
 
   
September 30, 2013
   
September 30, 2013
 
Net revenues
 
168
   
864
 
Operating costs
   
369
     
1,537
 
Gross margin
   
(201
)
   
(673
)
Direct general and administrative expenses less proceeds
   
989
     
1,176
 
Write off of goodwill and other intangible assets
   
6,338
     
6,338
 
     
(7,528
)
   
(8,187
)
Tax benefit
   
3,031
     
3,222
 
Loss from discontinued operations
 
(4,497
)
 
(4,965
)

The cash flow impact of the sale and closures is deemed immaterial for the consolidated statements of cash flows.
6. GOODWILL
 
The changes in the carrying amount of goodwill consisted of the following (in thousands):

   
Nine Months Ended
 
   
September 30, 2014
 
Beginning balance
 
143,955
 
Goodwill acquired during the period
   
15,266
 
Goodwill allocated to specific assets for business acquired in first six months of 2013
   
(1,680
)
Goodwill allocated to specific assets for business acquired - December 13 Acquisition
   
(7,500
)
Goodwill adjustments for purchase price allocation of businesses acquired
   
430
 
Ending balance
 
150,471
 

7. INTANGIBLE ASSETS, NET
 
Intangible assets, net as of September 30, 2014 and December 31, 2013 consisted of the following (in thousands):

   
September 30, 2014
   
December 31, 2013
 
Tradenames
 
12,414
   
9,814
 
Referral relationships, net of accumulated amortization of $2,336 and $1,582, respectively
   
8,945
     
3,959
 
Non-competition agreements, net of accumulated amortization of $2,240 and $1,950, respectively
   
1,256
     
706
 
   
22,615
   
14,479
 

Tradenames, referral relationships and non-competition agreements are related to the businesses acquired. The value assigned to tradenames has an indefinite life and is tested at least annually for impairment in conjunction with the Company’s annual goodwill impairment test. The value assigned to referral relationships is being amortized over their respective estimated useful lives which range from six to 16 years. Non-competition agreements are amortized over the respective term of the agreements which range from five to six years.
 
The following table details the amount of amortization expense recorded for intangible assets for the three and nine months ended September 30, 2014 and 2013 (in thousands):

   
Three Months Ended
   
Three Months Ended
   
Nine Months Ended
   
Nine Months Ended
 
   
September 30, 2014
   
September 30, 2013
   
September 30, 2014
   
September 30, 2013
 
Referral relationships
 
471
   
134
   
754
   
400
 
Non-competition agreements
   
141
     
102
     
290
     
293
 
Total
 
612
   
236
   
1,044
   
693
 
 
Based on the initial value of referral relationships and non-competition agreements in place as of September 30, 2014, the expected amount to be amortized in 2014 and thereafter by year is as follows (in thousands):
 
Referral Relationships
Non Competition Agreements
 
Annual
 
Annual
Years
Amount
Years
Amount
2014
       986
2014
       376
2015
       919
2015
       347
2016
       919
2016
       284
2017
       919
2017
       240
2018
       883
2018
       183
2019
       846
2019
       116
2020
       846
   
2021
       846
   
2022
       797
   
2023
       690
   
2024
       571
   
2025
       466
   
2026
         11
   

8. ACCRUED EXPENSES
 
Accrued expenses as of September 30, 2014 and December 31, 2013 consisted of the following (in thousands):

   
September 30, 2014
   
December 31, 2013
 
Salaries and related costs
 
11,081
   
11,686
 
Group health insurance claims
   
2,114
     
2,023
 
Credit balances and overpayments due to patients and payors
   
1,619
     
2,371
 
Other
   
4,267
     
4,545
 
Total
 
19,081
   
20,625
 

9. NOTES PAYABLE AND CREDIT AGREEMENT
 
Amounts outstanding under the Credit Agreement and notes payable as of September 30, 2014 and December 31, 2013 consisted of the following (in thousands):
 
   
September 30, 2014
   
December 31, 2013
 
Credit Agreement average effective interest rate of 2.3% at September 30, 2014 inclusive of unused fee
 
46,500
   
40,000
 
Various notes payable with $850 plus accrued interest due in the next year, interest accrues at 3.25% per annum at September 30, 2014
   
1,300
     
1,475
 
     
47,800
     
41,475
 
Less current portion
   
(850
)
   
(825
)
   
46,950
   
40,650
 

Effective December 5, 2013, the Company entered into an Amended and Restated Credit Agreement with a commitment for a $125.0 million revolving credit facility with a maturity date of November 30, 2018 (“Credit Agreement”). The Credit Agreement is unsecured and has loan covenants, including requirements that the Company comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Credit Agreement may be used for working capital, acquisitions, purchases of the Company’s common stock, dividend payments to the Company’s common shareholders, capital expenditures and other corporate purposes. The pricing grid is based on the Company’s consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.5% to 2.5% or the applicable spread over the Base Rate ranging from 0.1% to 1%. Fees under the Credit Agreement include an unused commitment fee ranging from 0.1% to 0.25% depending on the Company’s consolidated leverage ratio and the amount of funds outstanding under the Credit Agreement.
 
On September 30, 2014, $46.5 million was outstanding on the Credit Agreement resulting in $78.5 million of availability. As of September 30, 2014, the Company was in compliance with all of the covenants thereunder.
 
The Company generally enters into various notes payable as a means of financing a portion of its acquisitions. In conjunction with one of the acquisitions in 2014, the Company entered into a note payable in the amount of $400,000, payable in two annual equal installments of $200,000 plus any accrued and unpaid interest. Interest accrues at 3.25% per annum.   In conjunction with the acquisitions in 2013, the Company entered into notes payable in the aggregate amount of $1.3 million, each payable in two annual equal installments totaling $650,000 plus any accrued and unpaid interest. Interest accrues at 3.25% per annum, subject to adjustment.   In conjunction with the acquisitions in 2012, the Company entered into notes payable in the aggregate amount of $350,000, each payable in two annual equal installments totaling $175,000 plus any accrued and unpaid interest. Interest accrues at 3.25% per annum.

Aggregate annual payments of principal required pursuant to the Credit Agreement and the above notes payable subsequent to September 30, 2014 are as follows (in thousands):

   
September 30, 2014
 
During the twelve months ended September 30, 2015
 
850
 
During the twelve months ended September 30, 2016
   
450
 
During the twelve months ended September 30, 2019
   
46,500
 
Total
 
47,800
 

10. COMMON STOCK
 
From September 2001 through December 31, 2008, the Board authorized the Company to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of the Company’s common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of its common stock (“March 2009 Authorization”). In connection with the March 2009 Authorization, the Company amended the Credit Agreement to permit share repurchases of up to $15,000,000. The Company is required to retire shares purchased under the March 2009 Authorization.
 
Under the March 2009 Authorization, the Company has purchased a total of 859,499 shares. There is no expiration date for the share repurchase program. The Credit Agreement was further amended to permit the Company to purchase, commencing on October 24, 2012 and at all times thereafter, up to $15,000,000 of its common stock subject to compliance with covenants. There are currently an additional estimated 340,501 shares that may be purchased from time to time in the open market or private transactions depending on price, availability and the Company’s cash position. The Company did not purchase any shares of its common stock during the nine months ended September 30, 2014.
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following is a discussion of our historical consolidated financial condition and results of operations, and should be read in conjunction with (i) our historical consolidated financial statements and accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q; (ii) our Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission (the “SEC”) on March 11, 2014; and (iii) our management’s discussion and analysis of financial condition and results of operations included in our 2013 Form 10-K. This discussion includes forward-looking statements that are subject to risk and uncertainties. This discussion includes forward-looking statements that are subject to risk and uncertainties.  Actual results may differ substantially from the statements we make in this section due to a number of factors that are discussed in “Forward-Looking Statements” herein and “Part I – Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2013

References to “we,” “us,” “our” and the “Company” shall mean U.S. Physical Therapy, Inc. and its subsidiaries.

EXECUTIVE SUMMARY
 
Our Business
 
We operate outpatient physical therapy clinics that provide preventive and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. As of September 30, 2014, we operated 489 clinics in 42 states.
 
We also manage physical therapy facilities for third parties, primarily physicians, with 18 third-party facilities under management as of September 30, 2014.
 
On September 30, 2013, we sold the remainder of our physician services business.  The results of operations and the loss on the sale of the physician services business have been reclassified to discontinued operations for all periods presented.
 
The following discussion refers to continuing operations unless otherwise noted.
 
During the first nine months of 2014 and the year ended 2013, we acquired the following clinic groups:

Acquisition
Date
Acquired
Clinics
Date
         
April 2014 Acquisition
April 30
70%
13
April 30, 2014
August 2014 Acquisition
August 1
100%
3
August 1, 2014
February 2013 Acquisition
February 28
72%
9
February 28, 2013
April 2013 Acquisition
April 30
50%
5
April 30, 2013
May 2013 Acquisition
May 24
80%
5
May 24, 2013
December 9, 2013 Acquisition
December 9
60%
12
December 9, 2013
December 13, 2013 Acquisition
December 13
90%
11
December 13, 2013

The Company purchased interests in two partnerships which were previously classified as redeemable non-controlling interest on August 1, 2014. The interests in the partnerships purchased ranged from 10.0% to 35.0%.  In addition to the above clinic group acquisitions, in 2014, we acquired three individual clinic practices in separate transactions.  Two of the acquired clinics will operate as satellites of two of our partnerships and the other will be consolidated into an existing clinic.  Also, in 2013, we acquired three physical therapy clinic practices in separate transactions.
 
The results of operations of the acquired clinics have been included in our consolidated financial statements since the date of their acquisition.
Selected Operating and Financial Data
 
The following table presents selected operating and financial data that we believe are key indicators of our operating performance.
 
   
For the Three Months
   
For the Nine Months
 
   
Ended September 30, ,
   
Ended September 30,
 
   
2014
   
2013
   
2014
   
2013
 
Number of clinics, at the end of period
   
489
     
447
     
489
     
447
 
Working days
   
64
     
64
     
191
     
191
 
Average visits per day per clinic
   
23.0
     
21.3
     
22.6
     
21.3
 
Total patient visits
   
719,271
     
611,448
     
2,081,907
     
1,802,870
 
Net patient revenue per visit
 
$
105.92
   
$
105.27
     
106.18
   
$
105.96
 
 
RESULTS OF OPERATIONS

Three Months Ended September 30, 2014 Compared to the Three Months Ended September 30, 2013

Net revenues increased to $77.7 million for the three months ended September 30, 2014 (“2014 Third Quarter”) from $65.8 million for the three months ended September 30, 2013 (“2013 Third Quarter”) primarily due to an increase in visits of 107,800 from 611,500 for the 2013 Third Quarter to 719,300 for the 2014 Third Quarter and a slight increase in the average net patient revenue per visit for the 2014 Third Quarter to $105.92 from $105.27 in the 2013 Third Quarter.
 
Net income attributable to our common shareholders for the 2014 Third Quarter was $5.2 million versus $4.7 million for the 2013 Third Quarter. Net income was $0.43 per diluted share for the 2014 period and $0.38 for the 2013 period. Total diluted shares were 12.2 million for the 2014 Third Quarter and 12.1 million for the 2013 Third
Quarter.
 
Net Patient Revenues
 
Net patient revenues increased to $76.2 million for the 2014 Third Quarter from $64.3 million for the 2013 Third Quarter, an increase of $11.9 million, or 18.4%, due to visits of 80,600 from clinics opened and acquired between October 1, 2013 and September 30, 2014 (“New Clinics”) and an increase in visits of 27,200 from clinics opened or acquired prior to October 1, 2013 (“Mature Clinics”) and an increase in the net patient revenue per visit of $0.65.
 
Net patient revenues related to New Clinics amounted to $9.6 million for the 2014 Third Quarter and net patient revenues for Mature Clinics increased by $2.3 million for the 2014 Third Quarter as compared to the 2013 Third Quarter.
 
Net patient revenues are based on established billing rates less allowances and discounts for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under these programs are based on predetermined rates and are generally less than the established billing rates.
 
Other Revenues
 
Other revenues increased slightly in the 2014 Third Quarter compared to the 2013 Third Quarter.
 
Clinic Operating Costs
 
Clinic operating costs were $59.0 million, or 75.9% of net revenues, for the 2014 Third Quarter and $49.7 million, or 75.5% of net revenues, for the 2013 Third Quarter. The increase was primarily attributable to $8.1 million in operating costs of New Clinics and by an increase in operating costs of $1.2 million for Mature Clinics. Each component of clinic operating costs is discussed below:
Clinic Operating Costs—Salaries and Related Costs
 
Salaries and related costs increased to $41.8 million for the 2014 Third Quarter from $35.7 million for the 2013 Third Quarter, an increase of $6.1 million, or 17.0%. Salaries and related costs for New Clinics amounted to $5.6 million for the 2014 Third Quarter. Salaries and related costs for Mature Clinics increased by $0.5 million for the 2014 Third Quarter as compared to the 2013 Third Quarter.  Salaries and related costs as a percentage of net revenues were 53.8% for the 2014 Third Quarter and 54.3 % for the 2013 Third Quarter.
 
Clinic Operating Costs—Rent, Clinic Supplies, Contract Labor and Other
 
Rent, clinic supplies, contract labor and other were $16.1 million for the 2014 Third Quarter and $12.9 million for the 2013 Third Quarter. For New Clinics, rent, clinic supplies, contract labor and other amounted to $2.5 million for the 2014 Third Quarter. For Mature Clinics, rent, clinic supplies, contract labor and other increased by $0.7 million in the 2014 Third Quarter compared to the 2013 Third Quarter. Rent, clinic supplies, contract labor and other as a percentage of net revenues was 20.7% for the 2014 Third Quarter and 19.6% for the 2013 Third Quarter.
 
Clinic Operating Costs—Provision for Doubtful Accounts
 
The provision for doubtful accounts was $1.1 million for the 2014 Third Quarter and $1.1 million for the 2013 Third Quarter. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 1.4% for the 2014 Third Quarter and 1.7% for the 2013 Third Quarter.
 
Our allowance for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 5.1% at September 30, 2014, as compared to 4.4% at December 31, 2013. Our day’s sales outstanding were 41 days at September 30, 2014 and 39 days at December 31, 2013.
 
Corporate Office Costs
 
Corporate office costs, consisting primarily of salaries and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $7.5 million for the 2014 Third Quarter and $6.2 million for the 2013 Third Quarter. The increase was primarily due to an increase in the number of employees and the amount of accrued incentive compensation.  As a percentage of net revenues, corporate office costs were 9.6% for the 2014 Third Quarter and 9.5% for the 2013 Third Quarter.
 
Interest Expense
 
Interest expense increased to $0.2 million in the 2014 Third Quarter compared to $0.1 million in the 2013 Third Quarter due to a higher average outstanding balance under our revolving credit agreement during the 2014 period as compared to the 2013 period due to acquisitions.  At September 30, 2014, $46.5 million was outstanding under our revolving credit agreement.
 
Provision for Income Taxes
 
The provision for income taxes was $3.6 million for the 2014 Third Quarter and $3.0 million for the 2013 Third Quarter. During the 2014 and 2013 Third Quarters, we accrued state and federal income taxes at an effective tax rate (provision for taxes divided by the difference between income before taxes and net income attributable to non-controlling interests) of 41.0% and 39.0%, respectively.
 
Non-controlling Interests
 
Net income attributable to non-controlling interests, inclusive of discontinued operations, was $2.2 million for the 2014 Third Quarter and $2.0 million for the 2013 Third Quarter. Net income attributable to non-controlling interests, exclusive of discontinued operations, was $2.2 million for the 2014 Third Quarter and $2.1 million for the 2013 Third Quarter or as a percentage of operating income before corporate office costs was 11.7% for the 2014 Third Quarter and 13.0% for the 2013 Third Quarter.
Nine Months Ended September 30, 2014 Compared to the Nine Months Ended September 30, 2013
 
Net revenues increased to $225.7 million for the nine months ended September 30, 2014 (“2014 First Nine Months”) from $195.5 million for the nine months ended September 30, 2013 (“2013 First Nine Months”) primarily due to an increase in visits of 279,000 from 1,802,900 for the 2013 First Nine Months to 2,081,900 for the 2014 First Nine Months.
 
Net income attributable to our common shareholders for the 2014 First Nine Months was $15.9 million versus $13.6 million for the 2013 First Nine Months. Net income was $1.30 per diluted share for the 2014 period and $1.12 for the 2013 period. Total diluted shares were 12.2 million for the 2014 First Nine Months and 12.1 million for the 2013 First Nine Months.
 
Net Patient Revenues
 
Net patient revenues increased to $221.1 million for the 2014 First Nine Months from $191.0 million for the 2013 First Nine Months, an increase of $30.1 million, or 15.7%, due to an increase in visits of 185,000 from New Clinics and an increase in visits of 94,000 from Mature Clinics. The average net revenue per visit for the current period was $106.18 and $105.96 for the comparable 2013 period.
 
Net patient revenues related to New Clinics amounted to $22.6 million for the 2014 First Nine Months and net patient revenues for Mature Clinics increased by $7.5 million for the 2014 First Nine Months as compared to the 2013 First Nine Months primarily due to the acquisitions that occurred in the 2013 First Nine Months.
 
Net patient revenues are based on established billing rates less allowances and discounts for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under these programs are based on predetermined rates and are generally less than the established billing rates.
 
Other Revenues
 
Other revenues increased by $0.2 million in the 2014 First Nine Months to $4.6 million from $4.4 million in the 2013 First Nine Months.
 
Clinic Operating Costs
 
Clinic operating costs as a percentage of net revenues were $168.5 million, or 74.6% of net revenues, for the 2014 First Nine Months and $146.9 million, or 75.2% of net revenues, for the 2013 First Nine Months. The increase was primarily attributable to $18.4 million in operating costs of New Clinics and an increase in operating costs of $3.2 million for Mature Clinics. Each component of clinic operating costs is discussed below:
 
Clinic Operating Costs—Salaries and Related Costs
 
Salaries and related costs increased to $119.9 million for the 2014 First Nine Months from $105.3 million for the 2013 First Nine Months, an increase of $14.6 million, or 13.8%. Salaries and related costs for New Clinics amounted to $12.4 million for the 2014 First Nine Months. Salaries and related costs for Mature Clinics increased by $2.2 million for the 2014 First Nine Months as compared to the 2013 First Nine Months. Salaries and related costs as a percentage of net revenues were 53.1% for the 2014 First Nine Months and 53.9% for the 2013 First Nine Months.
 
Clinic Operating Costs—Rent, Clinic Supplies, Contract Labor and Other
 
Rent, clinic supplies, contract labor and other were $45.5 million for the 2014 First Nine Months and $38.2 million for the 2013 First Nine Months. For New Clinics, rent, clinic supplies, contract labor and other amounted to $5.8 million for the 2014 First Nine Months. For Mature Clinics, rent, clinic supplies, contract labor and other increased by $1.5 million in the 2014 First Nine Months compared to the 2013 First Nine Months. Rent, clinic supplies, contract labor and other as a percentage of net revenues was 20.2% for the 2014 First Nine Months and 19.5% for the 2013 First Nine Months.
Clinic Operating Costs—Provision for Doubtful Accounts
 
The provision for doubtful accounts was $3.1 million for the 2014 First Nine Months and $3.4 million for the 2013 First Nine Months. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 1.4% for the 2014 First Nine Months and 1.8% for the 2013 First Nine Months.
 
Our allowance for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 5.1% at September 30, 2014, as compared to 4.4% at December 31, 2013. Our days sales outstanding was 41 days at September 30, 2014 and 39 days at December 31, 2013.
 
Corporate Office Costs
 
Corporate office costs, consisting primarily of salaries and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $22.2 million for the 2014 First Nine Months and $19.2 million for the 2013 First Nine Months. The increase was primarily due to increase in the number of employees and the amount of accrued incentive compensation.  As a percentage of net revenues, corporate office costs were 9.8% for both the 2014 First Nine Months and 2013 First Nine Months.
 
Interest Expense
 
Interest expense increased to $0.8 million in the 2014 First Nine Months compared to $0.4 million in the 2013 First Nine Months due to a higher average outstanding balance under our revolving credit agreement during the 2014 period compared to the 2013 period due to acquisitions.  At September 30, 2014, $46.5 million was outstanding under our revolving credit agreement.

Provision for Income Taxes
 
The provision for income taxes was $11.0 million for the 2014 First Nine Months and $8.9 million for the 2013 First Nine Months. During the 2014 and 2013 First Nine Months, we accrued state and federal income taxes at an effective tax rate (provision for taxes divided by the difference between income before taxes and net income attributable to non-controlling interests) of 41.0% and 38.9%, respectively.
 
Non-controlling Interests
 
Net income attributable to non-controlling interests, inclusive of discontinued operations, was $7.3 million for the 2014 First Nine Months and $6.4 million for the 2013 First Nine Months. Net income attributable to non-controlling interests, exclusive of discontinued operations, was $7.3 million for the 2014 First Nine Months and $6.6 million for the 2013 First Nine Months or as a percentage of operating income before corporate office costs was 11.7% for the 2014 First Nine Months and 13.6% for the 2013 First Nine Months.

LIQUIDITY AND CAPITAL RESOURCES

We believe that our business is generating sufficient cash flow from operations to allow us to meet our short-term and long-term cash requirements, other than those with respect to future acquisitions. At September 30, 2014 and December 31, 2013, we had $15.8 million and $12.9 million, respectively, in cash. Although the start-up costs associated with opening new clinics and our planned capital expenditures are significant, we believe that our cash and unused availability under our revolving credit agreement are sufficient to fund the working capital needs of our operating subsidiaries, corporate costs, dividends, purchases of our common stock, accrued clinic closure costs, future clinic development and investments through at least March 2015. The amount outstanding under our revolving credit facility was $46.5 million at September 30, 2014 compared to $40.0 million at December 31, 2013.  At September 30, 2014, we had $78.5 million available under our revolving credit facility. Significant acquisitions would likely require financing under our revolving credit facility.
 
During the nine months ended September 30, 2014, $28.8 million was provided by operations and $6.5 million was drawn on our revolving credit agreement. The major uses of cash included: purchases of businesses ($12.2 million), distributions to non-controlling interest partners ($7.1 million), purchases of non-controlling interests ($5.0 million), payment of dividends to our shareholders ($4.4 million) and purchases of fixed assets ($3.9 million).
Effective December 5, 2013, we entered into an Amended and Restated Credit Agreement with a commitment for a $125.0 million revolving credit facility with a maturity date of November 30, 2018 (“Credit Agreement”). The Credit Agreement is unsecured and has loan covenants, including requirements that we comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Credit Agreement may be used for working capital, acquisitions, purchases of our common stock, dividend payments to our common shareholders, capital expenditures and other corporate purposes. The pricing grid is based on our consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.5% to 2.5% or the applicable spread over the Base Rate ranging from 0.1% to 1%. Fees under the Credit Agreement include an unused commitment fee ranging from 0.1% to 0.25% depending on our consolidated leverage ratio and the amount of funds outstanding under the Credit Agreement.  On September 30, 2014, $46.5 million was outstanding on the revolving credit facility resulting in $78.5 million of availability, and we were in compliance with all of the covenants thereunder.
 
Historically, we have generated sufficient cash from operations to fund our development activities and to cover operational needs. We plan to continue developing new clinics and making additional acquisitions. We also from time to time purchase the non-controlling interests in our Clinic Partnerships. Generally, any acquisition or purchase of non-controlling interests is expected to be accomplished using a combination of cash and financing. Any large acquisition would likely require financing.
 
We make reasonable and appropriate efforts to collect accounts receivable, including applicable deductible and co-payment amounts, in a consistent manner for all payor types. Claims are submitted to payors daily, weekly or monthly in accordance with our policy or payor’s requirements. When possible, we submit our claims electronically. The collection process is time consuming and typically involves the submission of claims to multiple payors whose payment of claims may be dependent upon the payment of another payor. Claims under litigation and vehicular incidents can take a year or longer to collect. Medicare and other payor claims relating to new clinics awaiting Medicare Rehab Agency status approval initially may not be submitted for six months or more. When all reasonable internal collection efforts have been exhausted, accounts are written off prior to sending them to outside collection firms. With managed care, commercial health plans and self-pay payor type receivables, the write-off generally occurs after the account receivable has been outstanding for at least 120 days.
 
We generally enter into various notes payable as a means of financing our acquisitions. Our present outstanding notes payable relate to certain of the acquisitions of businesses that occurred in 2014 and 2013. For those acquisitions, we entered into several notes payables aggregating $1.7 million. The notes are payable in equal annual installments of principal over two years plus any accrued and unpaid interest. Interest accrues at 3.25% per annum, subject to adjustment. In addition, we assumed leases with remaining terms of 1 month to 6 years for the operating facilities. At September 30, 2014, the balance on these notes payable was $1.3 million.

In conjunction with the above mentioned acquisitions, in the event that a limited minority partner’s employment ceases at any time after three years from the acquisition date, we have agreed to repurchase that individual’s non-controlling interest at a predetermined multiple of earnings before interest and taxes.
 
As of September 30, 2014, we have accrued $1.6 million related to credit balances and overpayments due to patients and payors.  This amount is expected to be paid  during the twelve months ended September 30, 2015.
 
From September 2001 through December 31, 2008, our Board of Directors (“Board”) authorized us to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of our common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of our common stock (“March 2009 Authorization”). In connection with the March 2009 Authorization, we amended our bank credit agreement to permit share repurchases of up to $15,000,000. We are required to retire shares purchased under the March 2009 Authorization. Effective October 24, 2012, we amended the Credit Agreement to permit us to purchase, commencing on October 24, 2012 and at all times thereafter, up to $15,000,000 of our common stock subject to compliance with covenants.
 
There is no expiration date for the share repurchase program. As of September 30, 2014, there are currently an additional estimated 341,000 shares that may be purchased from time to time in the open market or private transactions depending on price, availability and our cash position. We did not purchase any shares of our common stock during the nine months ended September 30, 2014.

FACTORS AFFECTING FUTURE RESULTS
 
The risks related to our business and operations include:
 
Changes as a result of healthcare reform legislation, and implementation thereof, may affect our business.
 
We depend upon reimbursement by third-party payors including Medicare and Medicaid.
 
Changes in economic conditions in the United States may have a material adverse impact on our business and financial condition.
 
We depend upon the cultivation and maintenance of relationships with physicians in our markets.
We depend upon our ability to recruit and retain experienced physical and occupational therapists.
 
Our revenues may fluctuate seasonally due to weather.
 
Our operations are subject to extensive regulation.
 
We operate in a highly competitive industry.
 
We may incur closure costs and losses.
 
Future acquisitions may use significant resources, may be unsuccessful and could expose us to unforeseen liabilities.
 
Certain of our internal controls, particularly as they relate to billings and cash collections, are largely decentralized at our clinic locations.
 
See Risk Factors in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2013.

Forward-Looking Statements
 
We make statements in this report that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to our financial condition, results of operations, plans, objectives, future performance and business. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we project. Included among such statements are those relating to opening new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:
 
changes as the result of government enacted national healthcare reform;
 
changes in Medicare guidelines and reimbursement or failure of our clinics to maintain their Medicare certification status;
 
business and regulatory conditions including federal and state regulations;
 
changes in reimbursement rates or payment methods from third party payors including government agencies and deductibles and co-pays owed by patients;
 
revenue and earnings expectations;
 
general economic conditions;
 
availability and cost of qualified physical and occupational therapists;
 
personnel productivity;
 
competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
 
acquisitions, purchase of non-controlling interests (minority interests) and the successful integration of the operations of the acquired businesses;
 
maintaining adequate internal controls;
 
availability, terms, and use of capital; and
 
weather and other seasonal factors.
 
Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see our periodic reports filed with the Securities and Exchange Commission (the “SEC”) for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement is no longer accurate.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
 
We do not maintain any derivative instruments, interest rate swap arrangements, hedging contracts, futures contracts or the like. Our primary market risk exposure is the changes in interest rates obtainable on our Credit Agreement. The interest on our Credit Agreement is based on a variable rate. At September 30, 2014, $46.5 million was outstanding under our Credit Agreement. Based on the balance of the Credit Agreement at September 30, 2014, any change in the interest rate of 1% would yield a decrease or increase in annual interest expense of $465,000.

ITEM 4. CONTROLS AND PROCEDURES.
 
(a) Evaluation of Disclosure Controls and Procedures
 
As of the end of the period covered by this report, the Company’s management completed an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded (i) that our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and (ii) that our disclosure controls and procedures are effective.
 
(b) Changes in Internal Control Over Financial Reporting
 
There have been no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II—OTHER INFORMATION

ITEM 6. EXHIBITS.
 
Exhibit Number
 
Description
     
31.1*
 
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
     
31.2*
 
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.
     
31.3*
 
Rule 13a-14(a)/15d-14(a) Certification of Corporate Controller.
     
32*
 
Certification Pursuant to 18 U.S.C 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS*
 
XBRL Instance Document
     
101.SCH*
 
XBRL Taxonomy Extension Schema Document
     
101.CAL*
 
XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*
 
XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*
 
XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE*
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
* Filed herewith
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned thereunto duly authorized.

 
U.S. PHYSICAL THERAPY, INC.
 
Date: November 7, 2014
By:
/s/ LAWRANCE W. MCAFEE
   
Lawrance W. McAfee
   
Chief Financial Officer
   
(duly authorized officer and principal financial and accounting officer)
 
 
By:
/s/ JON C. BATES
   
Jon C. Bates
   
Vice President/Corporate Controller

INDEX OF EXHIBITS

Exhibit Number
 
Description
     
 
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
 
 
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.
 
 
Rule 13a-14(a)/15d-14(a) Certification of Corporate Controller.
 
 
Certification Pursuant to 18 U.S.C 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
101.INS*
 
XBRL Instance Document
 
101.SCH*
 
XBRL Taxonomy Extension Schema Document
 
101.CAL*
 
XBRL Taxonomy Extension Calculation Linkbase Document
 
101.DEF*
 
XBRL Taxonomy Extension Definition Linkbase Document
 
101.LAB*
 
XBRL Taxonomy Extension Label Linkbase Document
 
101.PRE*
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
* Filed herewith
 
29